Voro Therapeutics and Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Gen Tumor-Activated ADCs
“Unlocking the full potential of highly potent payloads requires a new level of control over where and when activation occurs,” said Ugur Eskiocak, PhD, Co-Founder and CEO of Voro Therapeutics. “PrimeBody is designed to potentially provide that level of control through tumor-selective activation and expand the target universe to include antigens historically considered too broadly expressed. We believe this approach has the potential to fundamentally expand the therapeutic index of ADCs. We are excited to collaborate with Daiichi Sankyo, a global leader in ADC innovation with a proven track record of developing transformative medicines for patients.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the